Vascular Calcification: Bones, Blood Vessels, and Outcomes Ravi Thadhani, MD, MPH Associate Professor of Medicine Harvard Medical School Massachusetts.

Slides:



Advertisements
Similar presentations
AKI in Pediatrics Patrick D. Brophy MD Associate Professor
Advertisements

LINEE GUIDA, KDIGO E DIALISI PERITONEALE
MINERAL AND BONE DISORDERS IN CHRONIC KIDNEY DISEASE PEDRAM.AHMADPOOR SHAHID BEHESHTI MEDICAL UNIVERSITY.
Chronic Kidney Disease-Related Mineral and Bone Disorder: Public Health Problem Kerry Willis PhD National Kidney Foundation.
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
The future of haemodialysis in the UK RCP advanced medicine 2013 Cormac Breen Consultant Nephrologist Guy's and St Thomas' Hospitals London.
CKD in individuals with CKD
Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.
Measurement and preservation of residual renal function (RRF) in haemodialysis patients Elizabeth Lindley and David Keane Leeds Teaching Hospitals NHS.
Journal Club EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events – EVOLVE NEJM Dec 2012 Yuvaraj Thangaraj, M.D. Nephrology Fellow Division.
Chronic Kidney Disease in the Elderly Patient: Less May Be More Theodore F. Saad, MD Nephrology Associates, PA Chief, Section of Renal & Hypertensive Diseases.
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
Vitamin D and Immunity. Vitamin D Has Two Principal Effects on the Immune System 1.Vitamin D enhances some innate defenses against bacterial, viral or.
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
 Exemplary Care  Cutting-edge Research  World-class Education  Raghavan Murugan MD, MS, FRCP Associate Professor Dept. of Critical Care Medicine Clinical.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
On-going Research Studies in the Rosenfeld Lab *The role of RANK/RANKL in vascular complications of chronic kidney disease Effects of air pollution (diesel.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Arterial Calcification and Arterial Stiffness Alberto Avolio Department of Biomedical Sciences Faculty of Medicine and Health Sciences Macquarie University.
Chronic Kidney Disease-Mineral and Bone Disorder
Helical/Spiral CT. 2-4 slice 8-16 slice slice slice Helical/Spiral CT.
Clinical management of calciphylaxis Markus Ketteler, MD Division Chief of Nephrology at Klinikum Coburg, Academic Teaching Hospital of the University.
By MD., FAC.C Zagazig University. 1.Improve endothelial function 2.Stimulate angiogenesis 3.Mobilize bone-marrow derived stem cells 4.Reduce systemic.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Dialysis: outcome and complications. Introduction Outcomes – 20%+ of dialysis patients die each year, 3YS diabetics ~50% Technical complications –PD –Haemo.
AHA- Nov 12, 2005, Dallas P.K.Shah, MD Director of Cardiology and Atherosclerosis Research Center, Cedars-Sinai Medical Center, Professor of Medicine,
Introduction to ROS in the Cardiovascular System John F. Keaney, Jr., M.D. UMass Medical School Worcester, MA.
Monitoring CAC and IMT: A useful clinical tool? Cardiology Service Walter Reed Army Medical Center Walter Reed Army Health Care System NO CONFLICTS TO.
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
CKD Dr;BASHARDOOST. CKD –SOME DEFINITIONS IRREVERSIBLE LOSS OF GFR CKD results when a disease process damages the structural or functional integrity of.
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.
Innate immunity in cardiology: vessel (coronary spasm) and valve (aortic stenosis) Ming-Yow Hung, MD, FACC Division of Cardiology, Department of Internal.
Selected aspects of acid base physiology- acidosis in CKD
Predicting Progression in Diabetic Nephropathy: New Biomarker: sTNFR1* Circulating soluble Tumor Necrosis Factor Receptor 1.
Edward P. Sloan, MD, MPH Grant Opportunities in Emergency Medical Services & Bioterrorism Preparedness.
Comparison of Asymmetric DimethylArginine Levels and Coronary Artery Calcifications in Different Stages of Chronic Kidney Disease and Kidney Transplantation.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
John A. Kellum, MD, MCCM Professor of Critical Care Medicine, Medicine, Bioengineering and Clinical & Translational Science Vice Chair for Research Director,
High Coronary Calcification Scores Predict Mortality in Pre-Dialysis CKD Patients Reference: Haas MH. The risk of death in patients with a high coronary.
Pierre Delanaye, MD, PhD Department of Nephrology-Dialysis-Transplantation CHU Sart Tilman, Liège BELGIUM.
Soluble Klotho Pretreatment Improves Endothelial Dysfunction Induced By FGF23 Halee Patel, Neerupma Silswal, and Michael Wacker UMKC School of Medicine,
Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis :A randomized clinical trial Jay.
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.
Oral Phosphate Binders in Patients with Kidney Failure
The role of unknown risk factors in coronary heart disease
Volume 69, Issue 1, Pages (January 2006)
Pleiotropic effects of the non-calcium phosphate binder sevelamer
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
CKD–Mineral and Bone Disorder: Core Curriculum 2011
Current and future management of diabetic renal failure
ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.
Is there a link ? Atherosclerosis Coronary artery 11/14/2018
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
CKD–Mineral and Bone Disorder: Core Curriculum 2011
Bisphosphonate exposure and Atypical Femoral Fractures
Volume 72, Issue 6, Pages (September 2007)
Pleiotropic effects of the non-calcium phosphate binder sevelamer
Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps  Vincent M. Brandenburg, Markus.
Deprescribing Calcium-Based Phosphorus Binders in Dialysis Patients
Bisphosphonate safety and efficacy in chronic kidney disease
Volume 67, Pages S51-S58 (June 2005)
Role of vitamin D receptor activators on cardiovascular risk
Conclusion and Future Direction:
Baseline Characteristics of the Patients – Part I
Volume 69, Issue 1, Pages (January 2006)
Figure 1 Collagen is associated with ChemR23 expression in human and murine vascular smooth muscle cells. (A) Positive ... Figure 1 Collagen is associated.
Effect of sevelamer versus calcium-based binders on all-cause mortality in patients with CKD. Compared with calcium-based binders (CBBs), sevelamer significantly.
Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge?  Ellen G. Neven, Marc E. De Broe, Patrick.
Presentation transcript:

Vascular Calcification: Bones, Blood Vessels, and Outcomes Ravi Thadhani, MD, MPH Associate Professor of Medicine Harvard Medical School Massachusetts General Hospital Disclosures: Grant Support from Abbott

Courtesy of Kevin Martin, MD Calcified Plaque

Goodman WG et al, NEJM 2000

Schwarz et al, NDT Plaque Morphology in ESRD - Increased Media Thickness - Excess Calcification

Keelan et al, Circ 2000

London GM, JASN 2003

Okuno et al, AJKD 2007

DeLoach et al, NDT 2009 Aortic calcification and CVD events in Transplanted Patients

Haydar A et al, Kidney Int 2004

London GM, Kidney Int 2003

Klassen et al, JAMA 2002

Raggi P et al, Hypertension 2007

What has been linked with calcification? Ca P Ca X P Fetuin OPG LDL Matrix-Gla Protein hsCRP IL-6 TNF-  ??

CAC and Minerals…

Frequent dialysis reduces need for P binders, but is this the mechanism of benefit?

Normally, mesenchymal stem cells differentiate to adipocytes, osteoblasts, chondrocytes, and vascular smooth muscle cells (VSMC) Moe SM, JASN 2008

Kuro-o M et al, Nature 1997

Yumita et al, Tohuku J Exp Med 1996 Tsujikawa et al, Mol Endocrinol 2003

Tsujikawa H et al, Mol Endocrinol 2003

+D Users- D Users

All Groups CEU, CHB, and JPT +16% +21% p= p= Friedman, Afkarian, et al, In Press

Rodriguez M et al, Kidney Int 2008

Cardus A et al, JBMR 2007

CAC and LVH tightly linked

Who Progresses?

What do the Statin Data tell us? Fellström et al, NEJM 2009

55 yo F on HD for 8 years, dies of a CVA IVST=1.4cm; EF 60%, Mod-Sev Concentric Hypertrophy

Circulation 2009

Some Ongoing Trials Examining Calcification in ESRD PRIMO I & II – Paricalcitol and LVH, MRI of Aorta Included Cinacalcet + Low Dose Vitamin D (ADVANCE Trial) P-Binders and CAC: Sevelamer, Phos-Lo, Fosrenol Bisphosphonates and Calcification and BMD Phosphate Control and Calcification

Conclusions Calcification and Outcomes linked? Can Calcification be Modified? What interventions accelerate/decelerate calcification? What Biomarkers do we follow?